Stephanie Khan
Primary Care · Forest Hills, NYNPI 1366961526
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,500 of the $15,890 with a category attached, or 85.0%. 29 manufacturers reported payments, led by AbbVie at 40.3% of the total. Among primary care clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 527 payments — averaging $30.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Amgen$2K
- Teva Pharmaceuticals USA, Inc.$1K
- AstraZeneca$1K
- Novo Nordisk$740
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$547
- plus $4K from 23 others
What the payments were for
- Speaking & faculty fees$2,00013%
- Travel & lodging$901%
- Food & beverage$13,50085%
- Education$3002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 169 | $6,411 |
| Amgen(2 entities) | 66 | $2,000 |
| Teva Pharmaceuticals USA, Inc. | 43 | $1,137 |
| AstraZeneca | 27 | $1,118 |
| Novo Nordisk | 33 | $740 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $547 |
| Pfizer | 34 | $532 |
| Intra-sana Laboratories | 19 | $453 |
| Lilly USA, LLC | 16 | $432 |
| Astellas Pharma US Inc | 11 | $385 |
| Neurocrine Biosciences, Inc. | 16 | $381 |
| Scilex Pharmaceuticals Inc. | 20 | $364 |
| Incyte Corporation | 7 | $251 |
| Ironwood Pharmaceuticals, Inc | 10 | $207 |
| Lundbeck LLC | 6 | $197 |
| ANI Pharmaceuticals, Inc. | 9 | $170 |
| Medical Device Business Services, Inc. | 2 | $110 |
| Axsome Therapeutics, Inc. | 5 | $107 |
| Smith+Nephew | 2 | $48 |
| Biotronik Inc. | 1 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Arcutis Biotherapeutics, Inc. | 2 | $36 |
| Exact Sciences | 1 | $35 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Bayer | 1 | $28 |
| Dexcom, Inc. | 1 | $28 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Ardelyx, Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,890 in reported general payments places this provider in the 95th percentile of 239 primary care providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 65 | $127,461 |
| UbrelvyUbrogepant | 53 | $111,133 |
| Diclofenac Sodium | 157 | $102,361 |
| XifaxanRifaximin | 26 | $77,023 |
| OpzeluraRuxolitinib Phosphate | 26 | $61,246 |
| Dihydroergotamine Mesylate | 24 | $43,247 |
| VraylarCariprazine Hcl | 29 | $38,366 |
| LinzessLinaclotide | 44 | $36,383 |
| ZenpepLipase/Protease/Amylase | 19 | $32,477 |
| RybelsusSemaglutide | 19 | $31,848 |
| VtamaTapinarof | 21 | $28,535 |
| MounjaroTirzepatide | 23 | $23,641 |
| QuliptaAtogepant | 21 | $21,572 |
| RestasisCyclosporine | 29 | $18,058 |
| FarxigaDapagliflozin Propanediol | 24 | $16,751 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Vraylar, Linzess, Qulipta, Restasis | $6,411 | $225,512176 claims |
| PfizerNurtec Odt | $532 | $127,46165 claims |
| Incyte CorporationOpzelura | $251 | $61,24626 claims |
| Aimmune Therapeutics, Inc.Zenpep | $27 | $32,47719 claims |
| Novo NordiskRybelsus | $740 | $31,84819 claims |
| Lilly USA, LLCMounjaro | $432 | $23,64123 claims |
| AstraZenecaFarxiga | $1,118 | $16,75124 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $364 | $11,32422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 239 primary care providers in New York.
Other primary care in Forest Hills
- Dorothy KleinertNew York$27K
- Albert MarcanoJackson Heights$15K
- Elizabeth GattmanJamestown$10K
- Vanessa WangFlushing$10K
- Elizabeth SmithWaterloo$9K
- Eric RodriguezSyracuse$7K
- Natalie Sommerville-BrooksBrooklyn$6K
- Lisa PlanetaNew York$6K
- Pao-Ju TsengFlushing$6K
- Eliezer HernandezAlbany$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.